Abstract:e16144 Background: Pathological complete response (CR) and major pathological response (MPR) are associated with long-term survival after neoadjuvant/conversion surgery of HCC. The relationship between imaging and histopathological evaluations of response to combined TKI plus anti-PD-1 antibody treatment is unclear. Methods: This retrospective analysis included 23 patients with an initial diagnosis of unresectable HCC who underwent resection after combined TKI/anti-PD-1 antibody treatment between March 2019 and December 2020 at Zhongshan Hospital of Fudan University. MRI was performed before and after treatment and objective response rate (ORR; CR or partial response [PR]) was evaluated using RECIST 1.1 and mRECIST by investigator assessment (INV) and independent imaging review (IIR). Histopathological response was evaluated in resected tumor tissue using residual viable tumor (RVT; RVT area/total tumor bed surface area under 100X microscopy). MPR was defined as <10% RVT. The relationship between radiological reduction in tumor size and MPR was investigated using a receiver operating characteristic (ROC) curve. Results: Patients had a median age of 54.0 years, 91% were male and the average pre-treatment tumor diameter was 11.5±4.6 cm. Three had Barcelona Clinic Liver Cancer (BCLC) Stage A disease (China Liver Cancer Stage [CNLC] Ib, n=3), six had BCLC Stage B (CNLC IIa, n=1 and IIb n=5) and 14 had BCLC Stage C (CNLC IIIa, n=10 and IIIb, n=4). Patients received lenvatinib (n=19) or apatinib (n=4) plus anti-PD-1 antibodies (pembrolizumab [n=5], sintilimab [n=5], camrelizumab [n=10], treprizumab [n=2] or nivolumab [n=1]) followed by resection. Radiological responses are summarized in Table. An MPR or pathologic CR was achieved by 52.2% (12/23) and 39.1% (9/23) of patients, respectively. A correlation was observed between radiological responses using RECIST 1.1 and mRECIST and MPR (Fisher’s exact test; P=0.089 and 0.037, respectively). Using RECIST 1.1, the optimum diagnostic cutoff for MPR was a 26% reduction in tumor size, by both INV (area under ROC (AUC)=0.780, 95% CI: 0.580–0.981, sensitivity 83.3%, specificity 72.7%) and IIR (AUC=0.739, 95% CI: 0.527–0.951, sensitivity 75.0%, specificity 72.7%). Using mRECIST, the optimum cutoff for MPR was a 78% reduction in tumor size by INV (AUC=0.746, 95% CI: 0.538–0.954, sensitivity 58.3%, specificity 90.9%) and IIR (AUC=0.742, 95% CI: 0.532–0.953, sensitivity 66.7%, specificity 81.8%). Conclusions: Radiological response showed a degree of correlation with MPR in patients with advanced HCC receiving combined TKI and anti-PD-1 antibody therapy. Therefore, imaging evaluation may be used to predict a pathological response and further guide clinical treatment decisions. Response rates (n=23).[Table: see text]

Radiographic and α-fetoprotein response predict pathologic complete response to immunotherapy plus a TKI in hepatocellular carcinoma: a multicenter study

Tumor Radiomic Features on Pretreatment MRI to Predict Response to Lenvatinib Plus an Anti-PD-1 Antibody in Advanced Hepatocellular Carcinoma: A Multicenter Study

Systemic Chemotherapy Improves Outcome of Hepatocellular Carcinoma Patients Treated with Transarterial Chemoembolization

Radiological response as a predictor of pathological response to combined tyrosine kinase inhibitor (TKI) and anti-PD-1 antibodies in hepatocellular carcinoma (HCC).

Depth of Radiographic Response As an Independent Prognostic Factor for Patients with Initially Unresectable Hepatocellular Carcinoma Receiving Hepatectomy Following Targeted Therapy Plus Immunotherapy

Enhanced Efficacy of Direct Immunochemotherapy for Hepatic Cancer with Image-Guided Intratumoral Radiofrequency Hyperthermia

Early Alpha‐foetoprotein Response Associated with Treatment Efficacy of Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma

Early Complete Tumor Response As a Survival Predictor in Hepatocellular Carcinoma Patients Receiving Stereotactic Body Radiation Therapy

Early Alpha-Fetoprotein Response Predicts Treatment Efficacy of Antiangiogenic Systemic Therapy in Patients with Advanced Hepatocellular Carcinoma.

Limited Predictive or Prognostic Role of Tumor-Infiltrating Tissue-Resident Memory CD8 T Cells in Patients with Hepatocellular Carcinoma Receiving Immunotherapy

Predictive Factors for Complete Response and Recurrence after Transarterial Chemoembolization in Hepatocellular Carcinoma

Serologic, radiographic, and tissue-based markers associated with major pathologic response after treatment with neoadjuvant immunotherapy in patients with resectable hepatocellular carcinoma.

Prognostic Value of Pathological Response for Patients with Unresectable Hepatocellular Carcinoma Undergoing Conversion Surgery

Complete Response to Locoregional Therapy Plus Immunotherapy for Hepatocellular Carcinoma

Response to Pretransplant Downstaging Therapy Predicts Patient Outcome after Liver Transplantation for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus.

Serum alpha-fetoprotein response as a preoperative prognostic indicator in unresectable hepatocellular carcinoma with salvage hepatectomy following conversion therapy: a multicenter retrospective study

Association between early response of alpha-fetoprotein and treatment efficacy of systemic therapy for advanced hepatocellular carcinoma: A multicenter cohort study from China

Evaluation of efficacy of transcatheter arterial chemoembolization combined with computed tomography-guided radiofrequency ablation for hepatocellular carcinoma using magnetic resonance diffusion weighted imaging and computed tomography perfusion imaging: A prospective study

The characteristics and long-term survival of patients with colorectal liver metastases with pathological complete response after chemotherapy.

Influencing factors related to transcatheter arterial chemoembolization for hepatocellular carcinoma patients achieved tumor response

Combined CRAFITY score and α-fetoprotein response predicts treatment outcomes in patients with unresectable hepatocellular carcinoma receiving anti-programmed death-1 blockade-based immunotherapy